An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

• Published in: Current controlled trials in cardiovascular medicine Vol. 22; no. 1; pp. 508 - 17
• Main Authors: Sen, Arjune, Akinola, Mary, Tai, Xin You, Symmonds, Mkael, Davis Jones, Gabriel, Mura, Sergio, Galloway, Joanne, Hallam, Angela, Chan, Jane Y C, Koychev, Ivan, Butler, Chris, Geddes, John, Van Der Putt, Rohan, Thompson, Sian, Manohar, Sanjay G, Frangou, Eleni, Love, Sharon, McShane, Rupert, Husain, Masud
• Format: Journal Article
• Language: English
• Published: England BioMed Central 31-07-2021; BMC
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - drug therapy; Alzheimer's disease; Animals; Anti-seizure medication; Clinical trials; Cognition; Cognition & reasoning; Convulsions & seizures; Cross-Over Studies; Dementia; Double-Blind Method; Double-blind studies; Drug dosages; Epilepsy; Hospitals; Humans; Levetiracetam; Levetiracetam - adverse effects; Medicine; Memory; Mice; Neurology; Orthopedics; Patients; Pharmacists; Proof of Concept Study; Psychiatrists; Quality of Life; Randomised controlled trial; Rheumatology; Study Protocol; United Kingdom > UK; Pilot; Epilepsy; Randomised controlled trial; Cognition; Seizure; Anti-seizure medication; Dementia; Levetiracetam; Proof of concept
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-021-05404-4

Although Alzheimer's disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer's disease than age matched controls, may contribute to the loss of nerve cells and abnormal brain discharges can disrupt cognition. This aberrant electrical activity may therefore present potentially important drug targets. The anti-seizure medication levetiracetam can reduce abnormal cortical discharges and reverse memory deficits in a mouse model of Alzheimer's disease. Levetiracetam has also been shown to improve memory difficulties in patients with mild cognitive impairment, a precursor to Alzheimer's disease. Clinical use of levetiracetam is well-established in treatment of epilepsy and extensive safety data are available. Levetiracetam thus has the potential to provide safe and efficacious treatment to help with memory difficulties in Alzheimer's disease.
The proposed project is a proof of concept study to test whether levetiracetam can help cognitive function in people with dementia. We plan to recruit thirty patients with mild to moderate Alzheimer's disease with no history of previous seizures or other significant co-morbidity. Participants will be allocated to a double-blind placebo-controlled crossover trial that tests levetiracetam against placebo. Standardised scales to assess cognition and a computer-based touchscreen test that we have developed to better detect subtle improvements in hippocampal function will be used to measure changes in memory. All participants will have an electroencephalogram (EEG) at baseline. The primary outcome measure is a change in the computer-based touchscreen cognitive task while secondary outcomes include the effect of levetiracetam on mood, quality of life and modelling of the EEG, including time series measures and feature-based analysis to see whether the effect of levetiracetam can be predicted. The effect of levetiracetam and placebo will be compared within a given patient using the paired t-test and the analysis of covariance adjusting for baseline values.
This is the first study to evaluate if an anti-seizure medication can offer meaningful benefit to patients with Alzheimer's disease. If this study demonstrates at least stabilisation of memory function and/or good tolerability, the next step will be to rapidly progress to a larger study to establish whether levetiracetam may be a useful and cost-effective treatment for patients with Alzheimer's disease.
ClinicalTrials.gov NCT03489044 . Registered on April 5, 2018.